Welcome international healthcare professionals

This site is no longer supported and will not be updated with new content. You are welcome to browse and download all content already included in the site. Please note you will have to register your email address to access the site.

You are here

GNAQ/11 Mutations in Uveal Melanoma: Is YAP the Key to Targeted Therapy?

Cancer Cell, 6, 25, pages 714 - 715

GNAQ and GNA11 are frequently mutated in uveal melanoma, but they remain difficult therapeutic targets. In this issue of Cancer Cell, Feng and colleagues and Yu and colleagues demonstrate that the oncogenic activity of mutant GNAQ/11 is mediated at least in part through YAP, potentially uncovering a new therapeutic strategy.

Main Text

Malignant melanomas that arise from the iris, ciliary body, and choroid layers of the eye—collectively referred to as uveal melanomas—represent the most common primary cancer of the eye and the second most common form of melanoma ( Harbour, 2012 ). Despite the availability of highly effective treatments for eradicating the primary tumor, up to half of affected individuals later develop metastatic disease that is almost always fatal within a few months. Until recently, the identification of effective therapies for metastatic uveal melanoma has been hampered by a lack of known driver mutations. This situation has changed in recent years with the discovery of several common driver mutations, which has opened the door to rational targeted therapies ( Harbour, 2012 ).

Mutually exclusive mutations in the G protein-coupled receptor (GPCR) alpha subunits GNAQ and GNA11 (encoding Gq and G11 proteins, respectively) are present in ∼85% of uveal melanocytic tumors, including benign nevi, primary melanomas of all stages, and metastatic lesions ( Van Raamsdonk et al., 2010 ). This spectrum suggests that GNAQ/11 mutations occur early and may even represent initiating events in tumorigenesis ( Harbour, 2012 ). These mutations occur as single amino acid substitutions at residues Q209 or R183, and they abrogate the intrinsic GTPase activity that normally serves to inactivate the subunit. As such, these inactivating mutations result in constitutive activation of oncogenic Gq/11 subunits. The recessive nature of these mutations at the molecular level, despite their dominant action at the cellular level, has posed a major challenge for direct pharmacologic inhibition. Instead, most efforts have focused on inhibiting downstream targets of activated Gq/11. The best understood target of Gq/11 is phospholipase C beta (PLCβ), which cleaves phosphatidylinositol (4,5)-bisphosphate (PIP2) to yield diacylglycerol (DAG) and inositol triphosphate (IP3). Both products promote stimulation of protein kinase C (PKC), which leads to activation of the mitogen-activated protein kinase (MAPK or MEK) pathway and cell proliferation. MEK and PKC inhibitors inhibit the proliferation of Gq/11 mutant uveal melanoma cell lines in vitro (Ambrosini et al, 2012 and Wu et al, 2012). Yet, clinical trials so far have shown little or no activity of such agents in patients with metastatic uveal melanoma, raising the question of whether there may be other targets that are critical for therapeutic inhibition in cancers harboring oncogenic forms of Gq/11.

One such target may be the Hippo tumor suppressor pathway, which controls tissue growth and cell fate through the regulation of cell proliferation and apoptosis ( Harvey et al., 2013 ). Key effectors of the pathway include the homologous oncoproteins YAP and TAZ, which promote tissue growth by regulating the activity of transcription factors such as TEADs and SMADs. In most proliferating cells, YAP is localized in the nucleus in its active form. Hippo pathway signaling leads to phosphorylation of YAP by the serine/threonine-protein kinases LATS1/2, resulting in YAP inactivation and retention in the cytoplasm and degradation via the proteasome.

In this issue of Cancer Cell, Feng et al. (2014) and Yu et al. (2014) show that Gq/11 mutants found in uveal melanoma promote tumorigenesis by activating YAP. Mutant Gq/11, but not wild-type Gq/11, was found to trigger dephosphorylation and nuclear localization of YAP, associated with YAP-dependent transcription. Importantly, this activity of mutant Gq/11 is independent of PLCβ ( Feng et al., 2014 ). In uveal melanoma cell lines and human tumor samples, there was a strong correlation between the presence of Gq/11 mutations and activated YAP, as indicated by its nuclear localization and increased levels of unphosphorylated YAP ( Yu et al., 2014 ).

The question then arises as to whether this YAP activation by mutant Gq/11 is mediated solely through inhibition of LATS1/2. In their current article and in a recent publication by the same group ( Vaqué et al., 2013 ), Feng et al. (2014) show that activation of YAP by mutant Gq requires the guanine nucleotide exchange factor, Trio, and downstream small GTPases RhoA and Rac1. Activation of RhoA and Rac1 induces actin polymerization of G-actin to F-actin, triggering dissociation of the cytoskeletal-associated protein angiomotin (AMOT) from YAP, thereby allowing YAP to translocate from the cytoplasm to the nucleus to activate YAP-dependent transcription. Thus, mutant Gq/11 may activate YAP not only by inhibiting LATS1/2, but also by promoting actin polymerization independently of the canonical Hippo pathway.

A major implication of these findings is that traditional GPCR signaling through PLCβ may not be the only, or even the most important, mechanism for propagating mutant Gq/11 activity. Pharmacologic targeting of this novel YAP-dependent pathway may be critical for effective therapy against Gq/11 mutant cancers. Prompted by the recent identification of verteporfin as an inhibitor of YAP activity ( Liu-Chittenden et al., 2012 ), both groups show that verteporfin inhibits the growth of uveal melanomas in xenograft mouse models (Feng et al, 2014 and Yu et al, 2014). Because verteporfin is a well-tolerated agent with a favorable systemic toxicity profile, further work is warranted to explore the therapeutic potential of this and other porphyrin derivatives in metastatic uveal melanoma.

Although these findings are promising, it is unlikely that inhibition of mutant Gq/11 signaling alone will be sufficient for treating metastatic uveal melanoma. Mutant Gq and G11 are relatively weak oncoproteins that are only able to transform immortalized melanocytes that have been genetically altered to be deficient in the p53 and p16/CDK4/RB pathways ( Van Raamsdonk et al., 2009 ). Further, the vast majority of uveal melanocytic tumors with Gq/11 mutations are benign and do not metastasize, indicating that they require additional mutations to acquire metastatic potential. Thus, it will likely be necessary to target other driver mutations, perhaps in combination with Gq/11 inhibition. Because inactivating mutations in the tumor suppressor BRCA1-associated protein 1 (BAP1) are present in the vast majority of metastasizing uveal melanomas ( Harbour et al., 2010 ), BAP1 is a leading candidate for such therapeutic targeting. Nevertheless, these findings will play an important role in the ongoing quest for effective therapy against metastatic uveal melanoma.

References

  • Ambrosini et al., 2012 G. Ambrosini, C.A. Pratilas, L.X. Qin, M. Tadi, O. Surriga, R.D. Carvajal, G.K. Schwartz. Clin. Cancer Res.. 2012;18:3552-3561 Crossref
  • Feng et al., 2014 X. Feng, M.S. Degese, R. Iglesias-Bartolome, J.P. Vaque, A.A. Molinolo, M. Rodrigues, M.R. Zaidi, B.R. Ksander, G. Merlino, A. Sodhi, et al. Cancer Cell. 2014;25:831-845 this issue
  • Harbour, 2012 J.W. Harbour. Pigment Cell Melanoma Res. 2012;25:171-181 Crossref
  • Harbour et al., 2010 J.W. Harbour, M.D. Onken, E.D. Roberson, S. Duan, L. Cao, L.A. Worley, M.L. Council, K.A. Matatall, C. Helms, A.M. Bowcock. Science. 2010;330:1410-1413 Crossref
  • Harvey et al., 2013 K.F. Harvey, X. Zhang, D.M. Thomas. Nat. Rev. Cancer. 2013;13:246-257 Crossref
  • Liu-Chittenden et al., 2012 Y. Liu-Chittenden, B. Huang, J.S. Shim, Q. Chen, S.J. Lee, R.A. Anders, J.O. Liu, D. Pan. Genes Dev.. 2012;26:1300-1305 Crossref
  • Van Raamsdonk et al., 2009 C.D. Van Raamsdonk, V. Bezrookove, G. Green, J. Bauer, L. Gaugler, J.M. O’Brien, E.M. Simpson, G.S. Barsh, B.C. Bastian. Nature. 2009;457:599-602 Crossref
  • Van Raamsdonk et al., 2010 C.D. Van Raamsdonk, K.G. Griewank, M.B. Crosby, M.C. Garrido, S. Vemula, T. Wiesner, A.C. Obenauf, W. Wackernagel, G. Green, N. Bouvier, et al. N. Engl. J. Med.. 2010;363:2191-2199 Crossref
  • Vaqué et al., 2013 J.P. Vaqué, R.T. Dorsam, X. Feng, R. Iglesias-Bartolome, D.J. Forsthoefel, Q. Chen, A. Debant, M.A. Seeger, B.R. Ksander, H. Teramoto, J.S. Gutkind. Mol. Cell. 2013;49:94-108
  • Wu et al., 2012 X. Wu, M. Zhu, J.A. Fletcher, A. Giobbie-Hurder, F.S. Hodi. PLoS ONE. 2012;7:e29622 Crossref
  • Yu et al., 2014 F.-X. Yu, J.-S. Mo, G. Liu, Y.C. Kim, Z. Meng, L. Zhao, G. Peyman, H. Ouyang, W. Jiang, et al. Cancer Cell. 2014;25:822-830 this issue

Footnotes

1 Ocular Oncology Service, Bascom Palmer Eye Institute and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA

Corresponding author